Analysts Morgan Stanley initiate coverage of Attovia Therapeutics (ATOV) with Overweight rating and $39 price target
Several Wall Street firms have made significant analyst calls, highlighting potential growth opportunities and risks for various companies, which could influence investor decisions in the coming months.